Previous studies have demonstrated that the use of 200 IU of onabotulinumtoxinA (BTX) leads to significant improvements in the quality of life and symptoms of overactive bladder (OAB) in patients who do not respond to anticholinergic medications. These results are consistent with previous research suggesting a link between bladder wall thickness (BWT) and OAB pathophysiology. However, this study did not investigate any disparities in BWT between men and women, which should be the focus of future studies. All patients were informed of the off-label use of BTX and provided consent prior to receiving the injections. Even though the study design was retrospective and the sample size was small, the findings were consistent with those of previous randomized controlled trials.
Comparisons with Previous Studies
The study results were reinforced by the analysis of larger datasets and more recent randomized controlled trials, offering further evidence of the effectiveness of the intervention. For instance, in a randomized controlled trial conducted by Tincello et al., 200 IU BTX was administered to 240 patients with idiopathic OAB, resulting in a significant decrease in the frequency of urge incontinence episodes from 6.20 to 1.67 at month 6 compared to baseline, which supports the findings of our study (15). Concurrent improvements in the urinary frequency were also consistent with our results. Another randomized controlled study involving 34 patients found improvements in the urinary frequency and frequency of urinary incontinence episodes after receiving 200 IU BTX injections, similar to our findings (11).
Quality of Life and Symptom Improvement
Our study findings indicate that the mean quality of life (QoL) score significantly improved from 1.92 ± 0.74 to 3.52 ± 0.50 (p<0.001) following the treatment, suggesting a positive impact on the participants’ quality of life. To assess the quality of life of patients with OAB or urinary incontinence (UI), questionnaires such as the Incontinence Quality of Life (I-QoL) and Health-Related QoL (HRQoL) have been utilized in previous studies, reporting improvements similar to our study (4, 14, 17). Additional measures, such as the Overactive Bladder Symptom Score (OAB-SS) and Patient Global Impression of Improvement (PGI-I), have also shown comparable enhancements in patient outcomes (15, 16). Although our study participants reported improvements in their quality of life using a self-report 0–4 rating scale, future studies may benefit from incorporating both self-report and objective measures to obtain a more comprehensive understanding of the impact of interventions on QoL.
Dose-Response Relationships and Adverse Effects
While there is no definitive consensus on the optimal dose of botulinum toxin for treating idiopathic OAB or UI, a study by Dmochowski et al. investigated the relationship between dose response and adverse effects in both male and female patients. Statistically significant improvements in QoL scores and UI episodes were observed at doses of 150 IU or higher (14). These findings suggest that the optimal dose of BTX for the treatment of overactive bladder syndrome may be 150 IU or higher. However, higher doses are associated with an increased need for CIC. In our study, administering BTX at a dose of 200 IU resulted in significant improvements in UI symptoms and QoL without requiring CIC. The efficacy of the intervention was consistent with that of other studies, and the lower incidence of adverse effects may be attributed to the smaller sample size.
The most common adverse effects associated with botulinum toxin injections include the need for CIC due to increased post-void residual (PVR) and urinary retention, followed by urinary tract infections (UTIs) (10). The incidence of these adverse effects is dose-dependent, with urinary retention rates ranging from 16% to 43% and UTI rates ranging from 8.6% to 44% in studies examining botulinum toxin injections at a dose of 200 IU (11,12,15,22). None of our patients experienced urinary retention or increased PVR necessitating CIC, while only two patients developed UTIs. This observation may be due to the small sample size, which limits the analysis of the adverse effects..
Injection Technique and Bladder Wall Thickness
Botulinum toxin is administered to the detrusor muscle while avoiding the ureteral orifices and trigones to prevent vesicoureteral reflux or urinary tract infections (2). A study advocating injections in regions rich in neurons, such as the trigone and floor of the bladder, indicated that this approach prevented an increase in PVR during the follow-up after treatment (23). In our study, the trigone and ureteral orifices were spared, and no cases of urinary retention or increased PVR requiring CIC were observed after the injections.
Bladder wall thickness is known to increase due to fibrosis, edema, or inflammation and plays a crucial role in the pathophysiology of OAB. Previous studies have utilized ultrasound as an affordable, noninvasive, and widely accessible diagnostic tool to measure bladder wall thickness and diagnose OAB. These studies have demonstrated statistically significant reductions in bladder wall thickness following anticholinergic therapy compared with baseline (16, 17, 24). In our study, we observed statistically significant reductions in bladder wall thickness at the month 6 visit after BTX injections. Comperat et al. reported a lower level of bladder fibrosis in patients who received BTX injections than in those who did not, consistent with our findings (18).
Limitations
The limitations of this study include its retrospective design, absence of a control group, small sample size, and reliance on self-reported measures of quality of life. Future research should incorporate prospective studies with control groups to validate these findings and examine the dose-response relationship. Additionally, investigations should incorporate longitudinal designs to understand the temporal dynamics of these relationships better and assess potential confounding variables that may influence observed outcomes.
DISCUSSION
Previous studies have demonstrated that the use of 200 IU of onabotulinumtoxinA (BTX) leads to significant improvements in the quality of life and symptoms of overactive bladder (OAB) in patients who do not respond to anticholinergic medications. These results are consistent with previous research suggesting a link between bladder wall thickness (BWT) and OAB pathophysiology. However, this study did not investigate any disparities in BWT between men and women, which should be the focus of future studies. All patients were informed of the off-label use of BTX and provided consent prior to receiving the injections. Even though the study design was retrospective and the sample size was small, the findings were consistent with those of previous randomized controlled trials.
Comparisons with Previous Studies
The study results were reinforced by the analysis of larger datasets and more recent randomized controlled trials, offering further evidence of the effectiveness of the intervention. For instance, in a randomized controlled trial conducted by Tincello et al., 200 IU BTX was administered to 240 patients with idiopathic OAB, resulting in a significant decrease in the frequency of urge incontinence episodes from 6.20 to 1.67 at month 6 compared to baseline, which supports the findings of our study (15). Concurrent improvements in the urinary frequency were also consistent with our results. Another randomized controlled study involving 34 patients found improvements in the urinary frequency and frequency of urinary incontinence episodes after receiving 200 IU BTX injections, similar to our findings (11).
Quality of Life and Symptom Improvement
Our study findings indicate that the mean quality of life (QoL) score significantly improved from 1.92 ± 0.74 to 3.52 ± 0.50 (p<0.001) following the treatment, suggesting a positive impact on the participants’ quality of life. To assess the quality of life of patients with OAB or urinary incontinence (UI), questionnaires such as the Incontinence Quality of Life (I-QoL) and Health-Related QoL (HRQoL) have been utilized in previous studies, reporting improvements similar to our study (4, 14, 17). Additional measures, such as the Overactive Bladder Symptom Score (OAB-SS) and Patient Global Impression of Improvement (PGI-I), have also shown comparable enhancements in patient outcomes (15, 16). Although our study participants reported improvements in their quality of life using a self-report 0–4 rating scale, future studies may benefit from incorporating both self-report and objective measures to obtain a more comprehensive understanding of the impact of interventions on QoL.
Dose-Response Relationships and Adverse Effects
While there is no definitive consensus on the optimal dose of botulinum toxin for treating idiopathic OAB or UI, a study by Dmochowski et al. investigated the relationship between dose response and adverse effects in both male and female patients. Statistically significant improvements in QoL scores and UI episodes were observed at doses of 150 IU or higher (14). These findings suggest that the optimal dose of BTX for the treatment of overactive bladder syndrome may be 150 IU or higher. However, higher doses are associated with an increased need for CIC. In our study, administering BTX at a dose of 200 IU resulted in significant improvements in UI symptoms and QoL without requiring CIC. The efficacy of the intervention was consistent with that of other studies, and the lower incidence of adverse effects may be attributed to the smaller sample size.
The most common adverse effects associated with botulinum toxin injections include the need for CIC due to increased post-void residual (PVR) and urinary retention, followed by urinary tract infections (UTIs) (10). The incidence of these adverse effects is dose-dependent, with urinary retention rates ranging from 16% to 43% and UTI rates ranging from 8.6% to 44% in studies examining botulinum toxin injections at a dose of 200 IU (11,12,15,22). None of our patients experienced urinary retention or increased PVR necessitating CIC, while only two patients developed UTIs. This observation may be due to the small sample size, which limits the analysis of the adverse effects..
Injection Technique and Bladder Wall Thickness
Botulinum toxin is administered to the detrusor muscle while avoiding the ureteral orifices and trigones to prevent vesicoureteral reflux or urinary tract infections (2). A study advocating injections in regions rich in neurons, such as the trigone and floor of the bladder, indicated that this approach prevented an increase in PVR during the follow-up after treatment (23). In our study, the trigone and ureteral orifices were spared, and no cases of urinary retention or increased PVR requiring CIC were observed after the injections.
Bladder wall thickness is known to increase due to fibrosis, edema, or inflammation and plays a crucial role in the pathophysiology of OAB. Previous studies have utilized ultrasound as an affordable, noninvasive, and widely accessible diagnostic tool to measure bladder wall thickness and diagnose OAB. These studies have demonstrated statistically significant reductions in bladder wall thickness following anticholinergic therapy compared with baseline (16, 17, 24). In our study, we observed statistically significant reductions in bladder wall thickness at the month 6 visit after BTX injections. Comperat et al. reported a lower level of bladder fibrosis in patients who received BTX injections than in those who did not, consistent with our findings (18).
Limitations
The limitations of this study include its retrospective design, absence of a control group, small sample size, and reliance on self-reported measures of quality of life. Future research should incorporate prospective studies with control groups to validate these findings and examine the dose-response relationship. Additionally, investigations should incorporate longitudinal designs to understand the temporal dynamics of these relationships better and assess potential confounding variables that may influence observed outcomes.